Adagene Inc. has announced the completion of enrollment in its Phase 2 trial for muzastotug, a significant milestone in the development of novel cancer therapies. This trial, which combines muzastotug with Merck's KEYTRUDA®, aims to optimize dosage for patients with microsatellite stable colorectal cancer. The completion of this enrollment is crucial as Adagene prepares to advance its clinical programs.

Adagene Inc. (Nasdaq: ADAG) is a clinical-stage biotechnology company focused on developing innovative antibody-based therapies. The company operates within the pharmaceutical preparations sector and has been making strides in transforming cancer treatment through its SAFEbody technology. Recent filings indicate that Adagene is an accelerated filer and an emerging growth company, reflecting its ongoing development and strategic partnerships.

According to the recent SEC filing dated November 9, 2026, Adagene confirmed that the second closing of its strategic investment from Sanofi is expected to occur around November 20, 2026. This investment follows the company's achievement of full Phase 2 enrollment, enabling an additional $8 million in funding. This brings Sanofi's total investment in Adagene to $25 million under the previously established Securities Purchase Agreement.

Peter Luo, Adagene's Chairman and President of R&D, emphasized the importance of this trial, stating, "Completing enrollment in this randomized trial is an important step toward identifying the dose regimen of muzastotug for the Phase 3 registration trial." This trial is pivotal for determining the future of muzastotug in treating colorectal cancer, particularly where traditional therapies have faced limitations.

The Phase 2 trial enrolled 60 patients and evaluated two different dosing regimens of muzastotug in combination with pembrolizumab. The primary endpoint is the overall response rate, with secondary endpoints including duration of response and progression-free survival. Initial results are anticipated in the first half of 2027, which could significantly influence treatment protocols for colorectal cancer.

Adagene's innovative approach, utilizing its SAFEbody technology, aims to enhance the safety and efficacy of antibody therapies, addressing challenges associated with existing treatments. The company maintains worldwide commercial rights to muzastotug, positioning it to capitalize on the potential success of this therapy.

As the industry continues to evolve, Adagene's advancements in clinical trials and strategic partnerships with companies like Sanofi highlight the growing focus on innovative cancer therapies. The completion of this trial enrollment marks a critical step in the company's journey to bring new treatments to market.

Looking ahead, Adagene's next steps will involve monitoring the outcomes of the Phase 2 trial and preparing for the anticipated Phase 3 trial, which will further evaluate muzastotug's effectiveness in treating colorectal cancer. The company is poised to provide updates on trial results and any subsequent developments in its clinical programs as they unfold.